Febrile Neutropaenia

Febrile neutropaenia is the combination of both:

Epidemiology and Risk Factors

Risk factors are all some form of immunosuppression, namely:

  • Chemotherapy
  • Organ transplant
  • Clozapine-induced agranulocytosis
  • Chronic granulomatous disease

Pathophysiology

Aetiology

Clinical Features

Diagnosis should be suspected in any haematology or oncology patient who has:

Neutropaenic sepsis may occur without fever or other infective features, and has a high mortality.

  • Received chemotherapy in the previous 14 days
  • Is neutropaenic

Assessment

History:

Exam:

Investigations

Bedside:

  • TTE
    • Endocarditis

Laboratory:

  • Blood
    • Cultures
      • Peripheral
      • Every indwelling line
      • Strictly prior to antibiotics
    • FBE
    • UEC
    • LFT
  • Faeces
    • Culture
    • Viral studies
    • C. difficile toxin

Imaging:

  • CXR
  • CT
    • Brain
    • Chest
    • Consider pan-scan

Other:

  • LP
    • Gram stain and culture

Diagnostic Approach and DDx

Management

Goals of management

Resuscitation:

Specific therapy:

  • Pharmacological
    • Aggressive antimicrobial therapy
      • Broad-spectrum anti-pseudomonal:
        • Tazocin 4.5g IV Q8H
        • Cefepime 2g IV Q8H
        • Ceftazedime 2g IV Q8H
      • With alterations or additions if:
        • Known or likely ESBL
          • Change to Meropenem 2g IV Q8H.
        • Known or likely MRSA
          • Add vancomycin
        • CLABSI
          • Add vancomycin
        • Severe sepsis/septic shock
          • Add gentamycin 4-7mg/kg
          • Add vancomycin
        • Suspected PJP
          • Add trimethoprim/sulfamethoxazole
        • Suspected HSV/CMV
          • Add acyclovir or ganciclovir
        • Fever persists at 48 hours
          • Add vancomycin
        • Fever persists at 96 hours
          • Add antifungal
            • Caspofungin
              For fluconazole-resistant candida.
            • Voriconazole
              If suspected pulmonary infection (poor caspofungin penetrance).
            • Amphotericin
              If concern for mucor, cryptococcus, or zygomycetes.
    • G-CSF
      • Stimulates neutrophil production, and release of immature neutrophils
        WCC, with a lesser degree of immunorecovery.
      • Associated with↓ infection severity
      • Continue until neutrophil count >1×109/L
  • Procedural
  • Physical

Supportive care:

Disposition:

Preventative:

Marginal and Ineffective Therapies

Anaesthetic Considerations

Complications

Prognosis

Poor prognosis associated with:

  • Number and extent of organ failures
    Multi-organ failure has close to 100% ICU mortality.
  • Allogenic transplant
  • Intubation
    VAP risk.
  • Renal disease requiring haemodialysis

Key Studies


References